NNVC News and Press, NanoViricides Inc. From 05/06/24

2024-05-06 10:01:41 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...

NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 6, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says...

2024-05-02 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors should keep their eyes on the global nanotechnology market , which was valued at USD 3.78 billion in 2022 and is expected to reach USD 74.1 billion by 2032, growing at a CAGR of 3...

SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon. The Phase 1 clinical trial, ...

2024-02-15 06:38:29 ET More on NanoViricides Seeking Alpha’s Quant Rating on NanoViricides Historical earnings data for NanoViricides Financial information for NanoViricides Read the full article on Seeking Alpha For further details see: Na...

SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securi...

SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, explains that the demonstration of strong safety and tolerability of NV-CoV-2 o...

2024-01-29 12:52:58 ET More on NanoViricides Seeking Alpha’s Quant Rating on NanoViricides Historical earnings data for NanoViricides Financial information for NanoViricides Read the full article on Seeking Alpha For further details see: Na...

SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the healthy subjects part of the Phase 1a/1b Clinical Trial...

SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it is presenting at Biotech Showcase™ 2024. Event I...